A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
Jeff Schear/Getty Images for Johnson & Johnson
By Allison DeAngelis
May 5, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Johnson & Johnson said it discontinued a mid-stage study of its experimental drug to treat atopic dermatitis, after it…
Strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
